Resio Benjamin J, Hoag Jessica, Chiu Alexander, Monsalve Andres, Dhanasopon Andrew P, Boffa Daniel J, Blasberg Justin D
Section of Thoracic Surgery, Department of Surgery, Yale School of Medicine, New Haven, CT 06520-8062, USA.
J Thorac Dis. 2019 Mar;11(3):811-818. doi: 10.21037/jtd.2019.01.64.
Brain metastases are a major cause of mortality in patients with small cell lung cancer (SCLC). Prophylactic cranial irradiation (PCI) may improve survival among patients that respond to chemotherapy. Less is known about the outcomes of PCI following surgical resection of SCLC. The purpose of this study was to determine if patients who underwent initial surgical resection of SCLC benefit from PCI.
Adult patients in the National Cancer Database (NCDB) who underwent complete resection for primary, non-metastatic SCLC between 2004 and 2015 were identified. Patients that received preoperative chemotherapy or who did not receive appropriate adjuvant chemotherapy were excluded. Patients were grouped by treatment with or without cranial radiation within 8 months of resection. Survival was estimated using Kaplan-Meier and Cox multivariable analysis, adjusting for patient and tumor characteristics.
A total of 859 patients met inclusion criteria (202 received PCI and 657 did not). Kaplan-Meier analysis demonstrated that patients treated with PCI had significantly improved survival compared to no PCI (5-year survival 59% 50%, logrank P=0.0038). Multivariable cox models confirmed a significantly decreased hazard of death for patients receiving PCI (HR: 0.70, 95% CI: 0.55-0.89, P=0.003). In subset analyses, PCI was associated with significantly improved survival for node positive patients, but not node negative patients.
PCI is associated with increased survival for patients following surgical resection of SCLC. Patients with positive lymph nodes appear to benefit the most, while it remains unclear if patients with negative lymph nodes derive a benefit. Further study is warranted to clarify which subsets of patients should be treated with PCI.
脑转移是小细胞肺癌(SCLC)患者死亡的主要原因。预防性颅脑照射(PCI)可能会提高对化疗有反应的患者的生存率。关于SCLC手术切除后PCI的结果了解较少。本研究的目的是确定接受SCLC初始手术切除的患者是否能从PCI中获益。
在国家癌症数据库(NCDB)中确定2004年至2015年间接受原发性、非转移性SCLC完全切除的成年患者。排除接受术前化疗或未接受适当辅助化疗的患者。根据切除后8个月内是否接受颅脑放疗对患者进行分组。使用Kaplan-Meier和Cox多变量分析估计生存率,并对患者和肿瘤特征进行调整。
共有859例患者符合纳入标准(202例接受PCI,657例未接受)。Kaplan-Meier分析表明,与未接受PCI的患者相比,接受PCI治疗的患者生存率显著提高(5年生存率59%对50%,对数秩检验P=0.0038)。多变量Cox模型证实,接受PCI的患者死亡风险显著降低(HR:0.70,95%CI:0.55-0.89,P=0.003)。在亚组分析中,PCI与淋巴结阳性患者的生存率显著提高相关,但与淋巴结阴性患者无关。
PCI与SCLC手术切除后患者的生存率提高相关。淋巴结阳性的患者似乎获益最大,而淋巴结阴性的患者是否获益尚不清楚。有必要进一步研究以明确哪些患者亚组应接受PCI治疗。